ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
USWM, LLC (dba US WorldMeds)
USWM, LLC (dba US WorldMeds)
NeoTX Therapeutics Ltd.
Cancer Research UK
Tempus AI
Theratechnologies
Checkpoint Therapeutics, Inc.